Torstein R Meling1,2, Anna Latysheva3, Michele Da Broi4,5, Guro Jahr4, Harald Holte6, Klaus Beiske5,7, Kyrre Eeg Emblem8. 1. Department of Neurosurgery, Oslo University Hospital, 0027, Oslo, Norway. torsteinrmeling@gmail.com. 2. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. torsteinrmeling@gmail.com. 3. Department of Radiology, Oslo University Hospital, Oslo, Norway. 4. Department of Neurosurgery, Oslo University Hospital, 0027, Oslo, Norway. 5. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 6. Department of Oncology, Oslo University Hospital, Oslo, Norway. 7. Department of Pathology, Oslo University Hospital, Oslo, Norway. 8. Department of Diagnostic Physics, Oslo University Hospital, Oslo, Norway.
Abstract
PURPOSE: The purposes of this study are to study the impact of deep brain involvement on overall survival (OS) and progression-free survival (PFS) in intracranial primary CNS lymphoma (PCNSL), and to explore possible mechanisms for this impact using advanced MRI techniques. METHODS: Seventy-nine patients with histologically verified PCNSL were identified from a prospective clinical database of patients treated at Oslo University Hospital between 2003 and 2014. Patients were treated per standard chemotherapeutic regimens (N = 57) or no chemotherapy (N = 22). Anatomical MRIs were available in all patients to assess tumor load and location based on contrast agent enhancement visible on T1-weighted images. Diffusion MRIs were available in 33 (42%) patients and perfusion MRI in 13 (16%) patients that received active treatment. RESULTS: Across all patients, OS and PFS were 16.4 and 9.8 months, respectively. In multivariate analysis, MRI-based deep brain involvement (80%) was the only negative significant factor of OS (OR = 14.2; P < 0.005). While a reduced Karnofsky performance status was associated with deep brain involvement (P < 0.05), neither chemotherapy regimen, neurologic status, nor patient age were independent significant factors for OS or PFS in this setting. Compared to other tumors and healthy tissue levels, MRI perfusion showed more pathologic hemodynamic flow signatures in tumors with deep brain involvement. CONCLUSION: In intracranial PCNSL, the only significant prognostic factor for OS and PFS in multivariate analysis was age and deep brain involvement. While contingent on a small study sample, we hypothesize this may in part be explained by regional differences in vascular supply and delivery from a dysfunctional perfusion signature.
PURPOSE: The purposes of this study are to study the impact of deep brain involvement on overall survival (OS) and progression-free survival (PFS) in intracranial primary CNS lymphoma (PCNSL), and to explore possible mechanisms for this impact using advanced MRI techniques. METHODS: Seventy-nine patients with histologically verified PCNSL were identified from a prospective clinical database of patients treated at Oslo University Hospital between 2003 and 2014. Patients were treated per standard chemotherapeutic regimens (N = 57) or no chemotherapy (N = 22). Anatomical MRIs were available in all patients to assess tumor load and location based on contrast agent enhancement visible on T1-weighted images. Diffusion MRIs were available in 33 (42%) patients and perfusion MRI in 13 (16%) patients that received active treatment. RESULTS: Across all patients, OS and PFS were 16.4 and 9.8 months, respectively. In multivariate analysis, MRI-based deep brain involvement (80%) was the only negative significant factor of OS (OR = 14.2; P < 0.005). While a reduced Karnofsky performance status was associated with deep brain involvement (P < 0.05), neither chemotherapy regimen, neurologic status, nor patient age were independent significant factors for OS or PFS in this setting. Compared to other tumors and healthy tissue levels, MRI perfusion showed more pathologic hemodynamic flow signatures in tumors with deep brain involvement. CONCLUSION: In intracranial PCNSL, the only significant prognostic factor for OS and PFS in multivariate analysis was age and deep brain involvement. While contingent on a small study sample, we hypothesize this may in part be explained by regional differences in vascular supply and delivery from a dysfunctional perfusion signature.
Entities:
Keywords:
Lymphoma; MRI; Oncology; Prognostic factors; Surgery
Authors: Lauren E Abrey; Leah Ben-Porat; Katherine S Panageas; Joachim Yahalom; Brian Berkey; Walter Curran; Christopher Schultz; Steven Leibel; Diana Nelson; Minesh Mehta; Lisa M DeAngelis Journal: J Clin Oncol Date: 2006-11-20 Impact factor: 44.544
Authors: Eric M Bessell; Francesc Graus; Armando Lopez-Guillermo; Sarah A Lewis; Salvador Villa; Eugenia Verger; Josep Petit Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: Elisabeth Schorb; Benjamin Kasenda; Johannes Atta; Stephan Kaun; Anke Morgner; Georg Hess; Thomas Elter; Nikolas von Bubnoff; Martin Dreyling; Mark Ringhoffer; Stefan W Krause; Günter Derigs; Beate Klimm; D Niemann; Kristina Fritsch; Jürgen Finke; Gerald Illerhaus Journal: Haematologica Date: 2013-01-08 Impact factor: 9.941